Applied BioCode Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Applied BioCode şirketinin toplam hissedar öz sermayesi NT$577.0M ve toplam borcu NT$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NT$926.0M ve NT$349.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

NT$0

Borç

Faiz karşılama oranı	n/a
Nakit	NT$538.30m
Eşitlik	NT$577.03m
Toplam yükümlülükler	NT$348.97m
Toplam varlıklar	NT$926.00m

Son finansal sağlık güncellemeleri

We're Interested To See How Applied BioCode (TPE:6598) Uses Its Cash Hoard To Grow

Mar 31

Recent updates

Applied BioCode Corporation's (TWSE:6598) Shares Climb 33% But Its Business Is Yet to Catch Up

Jun 19

We're Interested To See How Applied BioCode (TPE:6598) Uses Its Cash Hoard To Grow

Mar 31

Introducing Applied BioCode (TPE:6598), A Stock That Climbed 11% In The Last Three Years

Feb 03

Breakeven On The Horizon For Applied BioCode Corporation (TPE:6598)

Dec 11

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 6598 'nin kısa vadeli varlıkları ( NT$795.1M ) kısa vadeli yükümlülüklerini ( NT$100.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: 6598 şirketinin kısa vadeli varlıkları ( NT$795.1M ) uzun vadeli yükümlülüklerini ( NT$248.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 6598 borçsuzdur.

Borcun Azaltılması: 6598 şirketinin 5 yıl önce borç/öz sermaye oranı 42.9% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 6598 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 6598 serbest nakit akışı her yıl % { 21 2.3 |round(1)}} yıl boyunca yeterli nakit akışına sahip olacaktır.

Applied BioCode Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Interested To See How Applied BioCode (TPE:6598) Uses Its Cash Hoard To Grow

Applied BioCode Corporation To Be Deleted From Other OTC

Recent updates

Applied BioCode Corporation to Report Q3, 2024 Results on Nov 11, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Applied BioCode Corporation to Report Q2, 2024 Results on Aug 22, 2024

Applied BioCode Corporation announced that it has received funding

New minor risk - Share price stability

Applied BioCode Corporation's (TWSE:6598) Shares Climb 33% But Its Business Is Yet to Catch Up

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use Only

Applied BioCode Announces CEO Changes

Full year 2023 earnings released: NT$2.01 loss per share (vs NT$2.26 loss in FY 2022)

Applied BioCode Corporation, Annual General Meeting, May 27, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: NT$0.53 loss per share (vs NT$0.54 loss in 3Q 2022)

Applied BioCode Appoints Beth Laderman as Chief Scientific Officer

Applied BioCode Corporation Announces the Resignation of Michael Sean Aye as Research and Development Officer

Second quarter 2023 earnings released: NT$0.75 loss per share (vs NT$0.39 loss in 2Q 2022)

Applied BioCode Corporation Announces the Change of Representative of Institutional Director

Applied Biocode Corporation Announces the Launch of the Fungal Panel Assay for Research Use

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Applied BioCode Corporation Announces Resignation of Craig Griz Adams as Sales Director

Insufficient new directors

Insufficient new directors

Insufficient new directors

Applied BioCode Corporation Announces the Change of Vice President of Operation

Applied BioCode Corporation Announces Change of Sales Director

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to NT$34.00

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Applied BioCode Obtains Emergency Use Authorization for CoV-2 Flu Plus Assay

Applied BioCode Launches 28 New Fungal Analyte Specific Reagents in the US

Third quarter 2021 earnings released: NT$0.75 loss per share (vs NT$0.28 loss in 3Q 2020)

We're Interested To See How Applied BioCode (TPE:6598) Uses Its Cash Hoard To Grow

Full year 2020 earnings released: NT$1.33 loss per share (vs NT$4.36 loss in FY 2019)

Applied BioCode Corporation, Annual General Meeting, Jun 07, 2021

Introducing Applied BioCode (TPE:6598), A Stock That Climbed 11% In The Last Three Years

New 90-day low: NT$49.05

New 90-day low: NT$55.00

Breakeven On The Horizon For Applied BioCode Corporation (TPE:6598)

New 90-day low: NT$72.70

Third quarter 2020 earnings released: NT$0.28 loss per share

New 90-day low: NT$77.80

New 90-day low: NT$92.50

First half earnings released

Applied BioCode Corporation To Be Deleted From Other OTC

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin